Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul;9(7):4052-4055.
doi: 10.21037/tcr-20-2188.

Trastuzumab-related cardiotoxicity: what do we know in 2020?

Jia Liu  1   2   3 , Shom Goel  4   5 , Jane McNeil Beith  2   3
Affiliations
Editorial

Trastuzumab-related cardiotoxicity: what do we know in 2020?

Jia Liu et al. Transl Cancer Res. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-2188). JL received grant funding from Astra Zeneca for unrelated research. SG has received research funding from Eli Lilly and G1 Therapeutics, and has served as an advisor to Eli Lilly and Novartis. JMB has served on Advisory Boards for Roche, Lilly, Novartis and Pfizer with payment to her Institution. Travel funded by Roche.

Comment on

  • A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
    de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber RD, Piccart-Gebhart M, Suter T. de Azambuja E, et al. Breast Cancer Res Treat. 2020 Jan;179(1):161-171. doi: 10.1007/s10549-019-05453-z. Epub 2019 Oct 11. Breast Cancer Res Treat. 2020. PMID: 31605311 Free PMC article.

References

    1. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. 10.1056/NEJMra043186 - DOI - PubMed
    1. Mohan N, Shen Y, Endo Y, et al. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther 2016;15:1321-31. 10.1158/1535-7163.MCT-15-0741 - DOI - PubMed
    1. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;(4):CD006243. - PMC - PubMed
    1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. 10.1056/NEJMoa052122 - DOI - PubMed
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. 10.1056/NEJMoa052306 - DOI - PubMed